Alvotech to attend Morgan Stanley Healthcare Conference, featuring investor meetings and a fireside chat by Dr. Balaji Prasad.
Quiver AI Summary
Alvotech, a biotechnology company focused on biosimilar medicines, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025. At the conference, Alvotech will engage with investors on September 9, and Dr. Balaji Prasad, the Chief Strategy Officer, will take part in a fireside chat on September 10 at 10:45 am EDT. A live webcast of this chat will be publicly accessible, with a recording available for replay afterward. Alvotech, which aims to lead in the biosimilar market, has launched two biosimilars and is developing several more for various medical conditions. The company has established strategic partnerships for global outreach and market expertise across multiple regions, including the US, Europe, and parts of Asia and South America. For additional details, interested parties can visit Alvotech's website or their investor portal.
Potential Positives
- Alvotech is participating in a prominent event, the Morgan Stanley 23rd Annual Global Healthcare Conference, enhancing its visibility in the biotech sector.
- Dr. Balaji Prasad, the Chief Strategy Officer, will engage directly with investors during a fireside chat, providing an opportunity to communicate company strategies and developments.
- A live webcast of the fireside chat will be available, expanding audience reach and accessibility to important corporate updates.
- Alvotech has a robust development pipeline targeting various therapeutic areas such as autoimmune disorders and cancer, showcasing its commitment to addressing diverse medical needs.
Potential Negatives
- None
FAQ
When is Alvotech participating in the Morgan Stanley Healthcare Conference?
Alvotech will participate in the conference from September 8-10, 2025.
Who from Alvotech will speak at the conference?
Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat.
How can I access the live webcast of the fireside chat?
The live webcast can be accessed at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york.
What biosimilar medicines does Alvotech develop?
Alvotech develops biosimilars for autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer.
Where are Alvotech's commercial partnerships located?
Alvotech has partnerships in the US, Europe, Japan, China, and other global markets.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 23 institutional investors add shares of $ALVO stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC added 1,090,664 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,946,855
- MORGAN STANLEY removed 655,093 shares (-64.7%) from their portfolio in Q2 2025, for an estimated $5,974,448
- OAKTREE CAPITAL MANAGEMENT LP removed 304,807 shares (-16.3%) from their portfolio in Q2 2025, for an estimated $2,779,839
- GILDER GAGNON HOWE & CO LLC added 195,345 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,781,546
- NORGES BANK added 180,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,641,599
- POINTSTATE CAPITAL LP removed 125,300 shares (-10.7%) from their portfolio in Q2 2025, for an estimated $1,142,736
- ROYCE & ASSOCIATES LP added 102,031 shares (+59.7%) to their portfolio in Q2 2025, for an estimated $930,522
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
Full Release
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york . After the event, a recording will be available for replay for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
